The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Implications of the ICTAN trial of icotinib for resected EGFR-mutated stage II-IIIA NSCLC
Si-Yu Wang, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses the implications of findings from the ICTAN trial (NCT01996098) of adjuvant icotinib following adjuvant chemotherapy for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (NSCLC). Adjuvant chemotherapies are associated with a 60% reduction in the risk of disease recurrence and Dr Wang argues these therapies are necessary for EGFR-mutated NSCLC after complete resection. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
